Moderna Stock Slips as FDA Delays RSV Vaccine Approval

Key TakeawaysModerna said the Food and Drug Administration (FDA) has delayed its approval decision for the respiratory syncytial virus (RSV) vaccine.The biotech reported it was advised by regulators that their review wouldn't be completed until the end of the month, whereas previously it was expected on May 12.Moderna is moving to produce vaccines for other diseases now that demand for its COVID-19 shot has declined with the pandemic over. Moderna (MRNA) shares lost ground in intraday trading Friday as the ...